Business
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth Schlieren (Zurich), Switzerland, May 7, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced the appointment of I.V. Hall as Chief Operating Officer effective June 1, 2026. I.V. will succeed Sjoerd Musters, who will conclude his role as the current Chief Operating Officer. By mutual ag
About this update from Kuros Biosciences Ltd.
[{"type":"image","alt":"Kuros Biosciences AG","displaySize":"","headline":null,"caption":"Kuros Biosciences AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":53,"url":"https://media.zenfs.com/en/globenewswire.com/806763a848369caf74ba90fee6846b72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1TRPB0XkYNh8yEEYi6XKyQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc0/https://media.zenfs.com/en/globenewswire.com/806763a848369caf74ba90fee6846b72","width":300,"height":53},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/1TRPB0XkYNh8yEEYi6XKyQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc0/https://media.zenfs.com/en/globenewswire.com/806763a848369caf74ba90fee6846b72","width":300,"height":53}},"lazy":false},{"type":"text","content":"Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth ","length":147,"tagName":"p"},{"type":"text","content":"Schlieren (Zurich), Switzerland, May 7, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced the appointment of I.V. Hall as Chief Operating Officer effective June 1, 2026. I.V. will succeed Sjoerd Musters, who will conclude his role as the current Chief Operating Officer. By mutual agreement, Sjoerd will remain with the Company through August 1, 2026, to ensure a smooth transition of responsibilities.","length":475,"tagName":"p"},{"type":"text","content":"This appointment reflects Kuros’ continued commitment to the organizational depth and operational infrastructure required to deliver on its innovative pipeline strategy. I.V. brings more than 30 years of medical device leadership experience with deep expertise in R&D, product development, commercialization, and strategic operations. He is widely recognized in the orthopedic trauma and extremities markets, making his appointment particularly relevant as Kuros continues to strengthen its presence across numerous musculoskeletal applications and accelerate the organic pipeline development.","length":597,"tagName":"p"},{"type":"text","content":"I.V. joins Kuros following a distinguished career spanning orthopedic trauma, surgical infection prevention, and cardiology. He spent 27 years with DePuy Synthes, a Johnson & Johnson company (formerly Synthes), where he held positions of wo...